Alps Advisors Inc. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,764 shares of the biopharmaceutical company’s stock after purchasing an additional 13,556 shares during the period. Alps Advisors Inc. owned 0.10% of Halozyme Therapeutics worth $2,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of HALO. Teacher Retirement System of Texas bought a new position in Halozyme Therapeutics in the second quarter worth approximately $129,000. Arrowstreet Capital Limited Partnership bought a new position in Halozyme Therapeutics in the second quarter worth approximately $131,000. Prudential Financial Inc. grew its stake in Halozyme Therapeutics by 8.7% in the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 940 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Halozyme Therapeutics in the second quarter worth approximately $171,000. Finally, Amalgamated Bank grew its stake in Halozyme Therapeutics by 5.3% in the second quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 705 shares in the last quarter. Institutional investors and hedge funds own 83.28% of the company’s stock.
Shares of Halozyme Therapeutics, Inc. (NASDAQ HALO) traded down $0.43 during mid-day trading on Monday, reaching $18.18. The company had a trading volume of 1,385,000 shares, compared to its average volume of 1,426,612. The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics, Inc. has a one year low of $9.68 and a one year high of $19.37.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). The firm had revenue of $63.73 million during the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The business’s revenue was up 100.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.23) EPS. analysts forecast that Halozyme Therapeutics, Inc. will post 0.09 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/13/alps-advisors-inc-buys-13556-shares-of-halozyme-therapeutics-inc-halo.html.
Several research analysts recently issued reports on HALO shares. Canaccord Genuity set a $16.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Jefferies Group LLC reissued an “underperform” rating and issued a $7.00 price objective (up previously from $6.75) on shares of Halozyme Therapeutics in a research note on Thursday, August 10th. Piper Jaffray Companies set a $20.00 target price on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Friday, August 11th. Finally, BidaskClub cut Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $17.75.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.